Literature DB >> 25120743

Recurrent inflammatory myofibroblastic tumors harboring PIK3CA and KIT mutations.

Cheng-Fang Li1, Chun-Xia Liu2, Bing-Cheng Li1, Yao-Yuan Shen1, Xiao-Bin Cui2, Wei Liu1, Hong-Chao Dong1, Li-Juan Pang2, Wei-Hua Liang1, Feng Li2.   

Abstract

Inflammatory myofibroblastic tumour (IMT) is a relatively rare soft tissue malignancy. It exhibits locally aggressive behavior with a tendency for local recurrence and rare metastasis, and rare recurrent IMTs may show histological progression. The genetic hallmark of IMT is ALK rearrangement from chromosome arm 2p, but gene mutations involved in IMT remain poorly understood. The aim of the present study was to perform a pairwise comparison of the gene mutations occurring in primary and recurrent IMT from the same patient. We conducted a high-throughput analysis of 238 known mutations of 19 oncogenes in pairwise comparison primary and recurrent samples from 2 patients of IMT using Sequenom MassARRAY technology. Our results revealed 2 mutations in 2 recurrent lesion samples, including one in exon 11 of the KIT gene, resulting in a T-C substitution at position 1727 (L576P), the recurrent sample underwent histologic progression with "pleomorphic undifferentiated sarcoma-like" transformation; the other mutation was in exon 19 of the phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha (PIK3CA) gene, resulting in a G-A substitution at position 1624 (E542K). Moreover, no any mutation was found in the primary lesion samples from 2 patients. Our findings suggest that variable genome changes might be present in IMT, especially during the progression from a primary tumour to recurrence. To the best of our knowledge, no such longitudinal study of IMT has been undertaken previously.

Entities:  

Keywords:  Inflammatory myofibroblastic tumour; MassARRAY; gene mutation; recurrent tumour

Mesh:

Substances:

Year:  2014        PMID: 25120743      PMCID: PMC4128978     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  31 in total

1.  Progression of inflammatory myofibroblastic tumor (inflammatory pseudotumor) of soft tissue into sarcoma after several recurrences.

Authors:  L R Donner; R A Trompler; R R White
Journal:  Hum Pathol       Date:  1996-10       Impact factor: 3.466

2.  PIK3CA mutations in in situ and invasive breast carcinomas.

Authors:  Alexander Miron; Maria Varadi; Daniel Carrasco; Hailun Li; Lauren Luongo; Hee Jung Kim; So Yeon Park; Eun Yoon Cho; Gretchen Lewis; Sarah Kehoe; J Dirk Iglehart; Deborah Dillon; D Craig Allred; Laura Macconaill; Rebecca Gelman; Kornelia Polyak
Journal:  Cancer Res       Date:  2010-06-15       Impact factor: 12.701

3.  Activating c-KIT mutations in a subset of thymic carcinoma and response to different c-KIT inhibitors.

Authors:  L Schirosi; N Nannini; D Nicoli; A Cavazza; R Valli; S Buti; L Garagnani; G Sartori; F Calabrese; A Marchetti; F Buttitta; L Felicioni; M Migaldi; F Rea; F Di Chiara; M C Mengoli; G Rossi
Journal:  Ann Oncol       Date:  2012-02-21       Impact factor: 32.976

4.  A rapid, sensitive, reproducible and cost-effective method for mutation profiling of colon cancer and metastatic lymph nodes.

Authors:  Debora Fumagalli; Patrick G Gavin; Yusuke Taniyama; Seung-Il Kim; Hyun-Joo Choi; Soonmyung Paik; Katherine L Pogue-Geile
Journal:  BMC Cancer       Date:  2010-03-16       Impact factor: 4.430

5.  Different prognostic roles of mutations in the helical and kinase domains of the PIK3CA gene in breast carcinomas.

Authors:  Mattia Barbareschi; Fiamma Buttitta; Lara Felicioni; Sabrina Cotrupi; Fabio Barassi; Maela Del Grammastro; Antonella Ferro; Paolo Dalla Palma; Enzo Galligioni; Antonio Marchetti
Journal:  Clin Cancer Res       Date:  2007-10-15       Impact factor: 12.531

6.  Activity of dasatinib against L576P KIT mutant melanoma: molecular, cellular, and clinical correlates.

Authors:  Scott E Woodman; Jonathan C Trent; Katherine Stemke-Hale; Alexander J Lazar; Sabrina Pricl; Giovanni M Pavan; Maurizio Fermeglia; Y N Vashisht Gopal; Dan Yang; Donald A Podoloff; Doina Ivan; Kevin B Kim; Nicholas Papadopoulos; Patrick Hwu; Gordon B Mills; Michael A Davies
Journal:  Mol Cancer Ther       Date:  2009-08-11       Impact factor: 6.261

Review 7.  Inflammatory myofibroblastic tumor of the bladder in children: what can be expected?

Authors:  C H Houben; A Chan; K H Lee; Y H Tam; K F To; W Cheng; C K Yeung
Journal:  Pediatr Surg Int       Date:  2007-04-19       Impact factor: 1.827

8.  Compound HRAS/PIK3CA mutations in Chinese patients with alveolar rhabdomyosarcomas.

Authors:  Chun-Xia Liu; Xiao-Ying Li; Cheng-Fang Li; Yun-Zhao Chen; Xiao-Bin Cui; Jian-Ming Hu; Feng Li
Journal:  Asian Pac J Cancer Prev       Date:  2014

9.  Prognostic role of PIK3CA mutation in colorectal cancer: cohort study and literature review.

Authors:  Xiaoyun Liao; Teppei Morikawa; Paul Lochhead; Yu Imamura; Aya Kuchiba; Mai Yamauchi; Katsuhiko Nosho; Zhi Rong Qian; Reiko Nishihara; Jeffrey A Meyerhardt; Charles S Fuchs; Shuji Ogino
Journal:  Clin Cancer Res       Date:  2012-02-22       Impact factor: 12.531

10.  Genomic and mutational profiling of ductal carcinomas in situ and matched adjacent invasive breast cancers reveals intra-tumour genetic heterogeneity and clonal selection.

Authors:  Lucia Hernandez; Paul M Wilkerson; Maryou B Lambros; Adriana Campion-Flora; Daniel Nava Rodrigues; Arnaud Gauthier; Cecilia Cabral; Vidya Pawar; Alan Mackay; Roger A'Hern; Caterina Marchiò; Jose Palacios; Rachael Natrajan; Britta Weigelt; Jorge S Reis-Filho
Journal:  J Pathol       Date:  2012-03-21       Impact factor: 7.996

View more
  2 in total

Review 1.  ALK-1-positive inflammatory myofibroblastic tumor of the thyroid complicated by Hashimoto's thyroiditis: report of a rare case and a literature review.

Authors:  Cheng-Fang Li; Xing-Long Wu; Jin-Jing Wang; Kai Wang; Su-Yuan Zhang; Jia-Jia Huang; Han-Zhong Hu; Hong Zheng
Journal:  Diagn Pathol       Date:  2020-05-19       Impact factor: 2.644

2.  Seek the Spindle Tumor in Submandibular Space.

Authors:  Deviprasad Dosemane; Urmila Khadilkar; Meera Khadilkar; Fayis Anwar
Journal:  Iran J Otorhinolaryngol       Date:  2019-05
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.